Menu

Image of the Day: Remodeled

Researchers use CRISPR-Cas9 to create transgenic Hydractinia symbiolongicarpus, a cnidarian, for the first time.

Jun 25, 2018
Sukanya Charuchandra
The transgenic Hydractinia symbiolongicarpus 
STEVEN SANDERS, DEPARTMENT OF SURGERY, UNIVERSITY OF PITTSBURGH, AND GREG GIBSON, CENTER FOR BIOLOGICAL IMAGING, UNIVERSITY OF PITTSBURGH

Researchers genetically manipulated a saltwater cnidarian, called Hydractinia symbiolongicarpus, using CRISPR-Cas9 technology. The research appeared as a preprint in bioRxiv on June 8.

Cnidarians, a phylum of invertebrate animals to which jellyfish, sea anemones, and corals belong, can be used as model systems for developmental biology, regeneration, and aging. This is the first time researchers have inserted fluorescent transgenes into the germline of a cnidarian, Hydractinia symbiolongicarpus, using CRISPR-Cas9. Specific proteins, visualized with the help of several different fluorescent tags, can be spotted in the transgenic organisms.  

S.M. Sanders et al., “CRISPR/Cas9-mediated gene knockin in the hydroid Hydractinia symbiolongicarpus,” bioRxiv, doi:10.1101/342592, 2018.

Clarification (June 26):  We erroneously implied this was the first time CRISPR-Cas9 was used in Cnidarians. In fact, this is the first time the technique has been used to insert transgenes into the germline.  

November 2018

Intelligent Science

Wrapping our heads around human smarts

Marketplace

Sponsored Product Updates

Slice® Safety Cutters for Lab Work

Slice® Safety Cutters for Lab Work

Slice cutting tools—which feature our patent-pending safety blades—meet many lab-specific requirements. Our scalpels and craft knives are well suited for delicate work, and our utility knives are good for general use.

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

Every minute counts when waiting for accurate diagnostic test results to guide critical care decisions, making today's clinical lab more important than ever. In fact, nearly 70 percent of critical care decisions are driven by a diagnostic test.

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC’s Genomics division announced it is transforming its branding under LGC, Biosearch Technologies, a unified portfolio brand integrating optimised genomic analysis technologies and tools to accelerate scientific outcomes.